ViCardia Therapeutics

Developing GP-531, a first-line treatment for acute heart f...


(

Private Fundraise

This company may be interested in raising funds from accredited investors. You must Request Access to see more information about this company.

Request Access 9

IMPROVING HEALTHSPAN FOR OPTIMUM LIFESPAN
ViCardia Therapeutics: Fast Facts

ViCardia Therapeutics is addressing the underlying cause of heart failure, a condition affecting over 65 million people globally, with novel treatment and research focused on mitochondrial dysfunction.

Our lead therapy, GP-531, is designed to improve total cardiac performance to reduce mortality in patients with worsening heart failure, increase healthspan to improve healthy lifespan.

Mitochondria, regarded as highly dynamic organelles with multiple functions, are taking center stage in the search for novel cardioprotective therapies that enhance the bioenergetics of the myocardium. The clinical evidence shows that mitochondrial dysfunction remains the underlying cause of Chronic Heart Failure that progresses over time to Acute Decompensated Heart Failure (ADHF), resulting in hospitalization for an acute event.

IMPROVING HEALTHSPAN FOR OPTIMUM LIFESPAN
Major Unmet Medical Need

Heart failure (HF) is the only category of cardiovascular disease for which the prevalence, incidence, hospitalization rate and total burden of mortality have increased over the past 30 years.

Following the first acute event and initial hospitalization, HF patients experience an often rapid decline in quality of life with frequent rehospitalizations and significant rates of morbidity/mortality. 

The current standard of care may provide short-term stabilization and symptomatic relief of HF, however, it fails to address the underlying pathophysiology.

IMPROVING HEALTHSPAN FOR OPTIMUM LIFESPAN
Addressing the Underlying Causes of HF

ViCardia is developing GP-531, a breakthrough therapy that uniquely targets mitochondrial dysfunction to improve total cardiac performance.

  • Abnormalities in synthesis of ATP-ADP cause mechanical failure of the heart.
  • Essentially, all aspects of heart muscle cells are altered in HF.
  • With HF the heart must work harder against greater resistance to pump adequate blood.
  • This causes cellular dysfunction and functional loss.

GP-531’s action is event-specific and site-specific, increasing levels of ATP only in areas of cellular dysfunction and functional loss.

Preclinical and clinical-stage research of our novel therapeutic support the hypothesis that GP-531 should:

IMPROVING HEALTHSPAN FOR OPTIMUM LIFESPAN
Compelling Results, Company Traction, Established Proof of Concept

IMPROVING HEALTHSPAN FOR OPTIMUM LIFESPAN
Summary of Clinical
Development Program

IMPROVING HEALTHSPAN FOR OPTIMUM LIFESPAN
The Science Behind GP-531

Mitochondrial dysfunction has been identified as the most important event in the development of chronic heart failure and the progression to acute decompensated heart failure (ADHF).

Dysfunctional mitochondria produce less cellular energy (ATP) and produce increased levels of reactive oxygen species (ROS), both of which lead to oxidative stress and ultimately to heart failure.

IMPROVING HEALTHSPAN FOR OPTIMUM LIFESPAN
ViCardia’s Executive Leadership Team 

The Business Plan area is locked. You must Request Access to this company to see more information including the Business Plan.


Request Access

N

No updates yet.




%

No backers yet.




Quick Signup TBD

You must have an account to do this!


the startups.com platform

Copyright © 2019 Startups.com. All rights reserved.

Fundable is a software as a service crowdfunding platform. Fundable is not a registered broker-dealer and does not offer investment advice or advise on the raising of capital through securities offerings. Fundable does not recommend or otherwise suggest that any investor make an investment in a particular company, or that any company offer securities to a particular investor. Fundable takes no part in the negotiation or execution of transactions for the purchase or sale of securities, and at no time has possession of funds or securities. No securities transactions are executed or negotiated on or through the Fundable platform. Fundable receives no compensation in connection with the purchase or sale of securities.